Suter L - Search Results

1

A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging.

Brunner G, Heinecke A, Falk TM, Ertas B, Blödorn-Schlicht N, Schulze HJ, Suter L, Atzpodien J, Berking C. Brunner G, et al. Among authors: suter l. JNCI Cancer Spectr. 2018 Jul 23;2(3):pky032. doi: 10.1093/jncics/pky032. eCollection 2018 Jul. JNCI Cancer Spectr. 2018. PMID: 31360859 Free PMC article.

2

A nine-gene signature predicting clinical outcome in cutaneous melanoma.

Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J. Brunner G, et al. Among authors: suter l. J Cancer Res Clin Oncol. 2013 Feb;139(2):249-58. doi: 10.1007/s00432-012-1322-z. Epub 2012 Oct 9. J Cancer Res Clin Oncol. 2013. PMID: 23052696

3

Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients.

Brunner G, Reitz M, Schwipper V, Tilkorn H, Lippold A, Biess B, Suter L, Atzpodien J. Brunner G, et al. Among authors: suter l. Cancer Biother Radiopharm. 2008 Aug;23(4):451-9. doi: 10.1089/cbr.2008.0473. Cancer Biother Radiopharm. 2008. PMID: 18771349

4

Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients.

Kuhlmann JD, Wimberger P, Wilsch K, Fluck M, Suter L, Brunner G. Kuhlmann JD, et al. Among authors: suter l. Clin Chem Lab Med. 2015 Mar;53(4):605-11. doi: 10.1515/cclm-2014-1064. Clin Chem Lab Med. 2015. PMID: 25741740

5

Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?

Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L. Ostmeier H, et al. Among authors: suter l. Cancer. 1999 Jun 1;85(11):2391-9. doi: 10.1002/(sici)1097-0142(19990601)85:11<2391::aid-cncr14>3.0.co;2-i. Cancer. 1999. PMID: 10357410 Clinical Trial.

6

Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics.

Goldmann T, Ribbert D, Suter L, Brode M, Otto F. Goldmann T, et al. Among authors: suter l. J Exp Clin Cancer Res. 1998 Dec;17(4):483-9. J Exp Clin Cancer Res. 1998. PMID: 10089072

7

Expression of MAGE genes in primary and metastatic cutaneous melanoma.

Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, et al. Brasseur F, et al. Among authors: suter l. Int J Cancer. 1995 Nov 3;63(3):375-80. doi: 10.1002/ijc.2910630313. Int J Cancer. 1995. PMID: 7591235

8

Prognostic immunohistochemical markers of primary human melanomas.

Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L. Ostmeier H, et al. Among authors: suter l. Br J Dermatol. 2001 Aug;145(2):203-9. doi: 10.1046/j.1365-2133.2001.04335.x. Br J Dermatol. 2001. PMID: 11531780

9

p-glycoprotein expression in malignant melanoma.

Fuchs B, Ostmeier H, Suter L. Fuchs B, et al. Among authors: suter l. J Cancer Res Clin Oncol. 1991;117(2):168-71. doi: 10.1007/BF01613142. J Cancer Res Clin Oncol. 1991. PMID: 1672531

10

Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters.

Otto FJ, Goldmann T, Biess B, Lippold A, Suter L, Westhoff U. Otto FJ, et al. Among authors: suter l. Oncology. 1999 Apr;56(3):208-14. doi: 10.1159/000011967. Oncology. 1999. PMID: 10202276

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

329 results

Search Page